Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1

Gene Therapy

Volumn 11, Issue 14, 2004, Pages 1170-1174

  Yague E ^a   Higgins, C F ^a   Raguz, S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Cancer; MDR1; Multidrug resistance; siRNA

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; MESSENGER RNA;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL LINE; EXPRESSION VECTOR; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC CODE; HUMAN; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; TREATMENT OUTCOME; GENE; GENE EXPRESSION REGULATION; GENETICS; LEUKEMIA; METABOLISM; METHODOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; GENE EXPRESSION REGULATION; GENE TARGETING; GENE THERAPY; GENES, MDR; HUMANS; LEUKEMIA; P-GLYCOPROTEIN; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 4243068680     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302269     Document Type: Article

References (38)

1. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
2. Jin S, Gorfajn B, Faircloth G, Scotto KW. Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 2000; 97: 6775-6779.
3. Synold TW, Dussault I, Forman BM. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 2001; 7: 584-590.
4. Yang JM, Vassil AD, Hait WN. Activation of phospholipase C induces the expression of the multidrug resistance (MDR1) gene through the Raf-MAPK pathway Mol Pharmacol 2001; 60: 674-680.
5. Cucco C, Calabretta B. In vitro and in vivo reversal of multidrug resistance in a human leukaemia-resistant cell line by mdr1 antisense oligodeoxynucleotides. Cancer Res 1996; 56: 4332-4337.
6. Marthinet E et al. Modulation of the typical multidrug resistance phenotype by targeting the MED-1 region of human MDR1 promoter. Gene Therapy 2000; 7: 1224-1233.
7. Wang FS et al. Retrovirus-mediated transfer of anti-MDR1 ribozymes fully restores chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum Gene Ther 1999; 10: 1185-1195.
8. Hannon GJ. RNA interference. Nature 2002; 418: 244-251.
9. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15: 188-200.
10. Brummelkamp TR, Bernards R, Agami R. A system for stable expression of short interfering RNAs in mammalian cells. Science 2002; 296: 550-553.
11. An DS et al. Efficient lentiviral vectors for short hairpin RNA delivery into human cells. Hum Gene Ther 2003; 14: 1207-1212.
12. Wu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003; 63: 1515-1519.
13. Nieth C, Priebsch A, Stege A, Lage H. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett 2003; 545: 144-150.
14. Batist G et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-15549.
15. Lage H, Dietel M. Multiple mechanisms confer different drug-resistant phenotypes in pancreatic carcinoma cells. J Cancer Res Clin Oncol 2002; 128: 349-357.
16. Mechetner E et al. Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998; 4: 389-398.
17. Muller C, Laurent G, Ling V. P-glycoprotein stability is affected by serum deprivation and high cell density in multidrug-resistant cells. J Cell Physiol 1995; 163: 538-544.
18. Frost BM et al. Pharmacokinetics of doxorubicin in children with acute lymphoblastic leukaemia: multi-institutional collaborative study. Med Pediatr Oncol 2002; 38: 329-337.
19. Yague E et al. P-glycoprotein (MDR1) expression in leukaemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J Biol Chem 2003; 278: 10344-10352.
20. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci USA 2002; 99: 6047-6052.
21. Hemann MT et al. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Nat Genet 2003; 33: 396-400.
22. Chi JT et al. Genomewide view of gene silencing by small interfering RNAs. Proc Natl Acad Sci USA 2003; 100: 6343-6346.
23. Uptain SM, Kane CM, Chamberlin MJ. Basic mechanisms of transcript elongation and its regulation. Annu Rev Biochem 1997; 66: 117-172.
24. Ramachandran C, Wellham LL. Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res 2003; 23: 2681-2690.
25. Abbas-Terki T et al. Lentiviral-mediated RNA interference. Hum Gene Ther 2002; 13: 2197-2201.
26. Rubinson DA et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
27. Stewart SA et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. Rna 2003; 9: 493-501.
28. Ivy SP et al. Correlation of P-glycoprotein expression and function in childhood acute leukaemia: a children's cancer group study. Blood 1996; 88: 309-318.
29. McKenna SL, Padua RA. Multidrug resistance in leukaemia. Br J Haematol 1997; 96: 659-674.
30. Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukaemia. Hematology (Am Soc Hematol Educ Program) 2003: 132-152.
31. O'Dwyer ME, Mauro MJ, Druker BJ. Recent advancements in the treatment of chronic myelogenous leukaemia. Annu Rev Med 2002; 53: 369-381.
32. Goldman JM, Melo JV. Chronic myeloid leukaemia-advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
33. Paterson SC, Smith KD, Holyoake TL, Jorgensen HG. Is there a cloud in the silver lining for imatinib? Br J Cancer 2003; 88: 983-987.
34. Mahon FX et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukaemia cell line models. Blood 2003; 101: 2368-2373.
35. Wohlbold L et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatimb mesylate (ST1571). Blood 2003; 102: 2236-2239.
36. Damm-Welk C, Fuchs U, Wossmann W, Borkhardt A. Targeting oncogenic fusion genes in leukaemias and lymphomas by RNA interference. Semin Cancer Biol 2003; 13: 283-292.
37. Tipping AJ, Deininger MW, Goldman JM, Melo JV. Comparative gene expression profile of chronic myeloid leukaemia cells innately resistant to imatinib mesylate. Exp Hematol 2003; 31: 1073-1080.
38. Agami R, Bernards R. Distinct initiation and maintenance mechanisms cooperate to induce G1 cell cycle arrest in response to DNA damage. Cell 2000; 102: 55-66.